Metabolic characterisation of transglutaminase 2 inhibitor effects in breast cancer cell lines.
AA9 inhibitor
MCF-7 cells, MDA-MB-231 cells
metabolomics
transglutaminase 2
transglutaminase 2 inhibitor
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
04
07
2023
received:
08
12
2022
accepted:
09
08
2023
medline:
16
11
2023
pubmed:
19
8
2023
entrez:
19
8
2023
Statut:
ppublish
Résumé
Transglutaminase 2 (TG2), which mediates post-translational modifications of multiple intracellular enzymes, is involved in the pathogenesis and progression of cancer. We used
Substances chimiques
Protein Glutamine gamma Glutamyltransferase 2
EC 2.3.2.13
Transglutaminases
EC 2.3.2.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5411-5433Subventions
Organisme : FAR2021
ID : FAR2191074
Organisme : FAR2021
ID : FIR2191318
Informations de copyright
© 2023 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Eckert RL, Fisher ML, Grun D, Adhikary G, Xu W & Kerr C (2015) Transglutaminase is a tumor cell and cancer stem cell survival factor. Mol Carcinog 54, 947-958.
Kim DS, Park SS, Nam BH, Kim IH & Kim SY (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66, 10936-109343.
Brown KD (2013) Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype. Breast Cancer Res Treat 137, 329-336.
Agnihotri N, Kumar S & Mehta K (2013) Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res 15, 202-211.
Herman JF, Mangala LS & Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25, 3049-3058.
Cao J & Huang W (2016) Compensatory increase of transglutaminase 2 is responsible for resistance to mTOR inhibitor treatment. PLoS ONE 11, e0149388.
Shinde A, Kulkoyluoglu Cotul E, Chen H, Smit A, Libring S, Solorio L & Wendt MK (2022) Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer. Mol Biomed 3, 19-30.
Mehta K, Fok J, Miller FR, Koul D & Sahin AA (2004) Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10, 8068-8076.
Karicheva O, Rodriguez-Vargas JM, Wadier N, Martin-Hernandez K, Vauchelles R, Magroun N, Tissier A, Schreiber V & Dantzer F (2016) PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-snail-E-cadherin axis. Oncotarget 7, 64109-64123.
Bianchi N, Brugnoli F, Grassilli S, Bourgeois K, Keillor JW, Bergamini CM, Aguiari G, Volinia S & Bertagnolo V (2021) The motility and mesenchymal features of breast cancer cells correlate with the levels and intracellular localization of transglutaminase type 2. Cell 10, 3059-3078.
Beninati S, Piacentini M & Bergamini CM (2017) Transglutaminase 2, a double face enzyme. Amino Acids 49, 415-423.
Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB & Mehta K (2012) Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 14, R4.
Lin HY, Kuei CH, Lee HH, Lin CH, Zheng JQ, Chiu HW, Chen CL & Lin YF (2020) The Gαh/phospholipase C-δ1 interaction promotes autophagosome degradation by activating the Akt/mTORC1 pathway in metastatic triple-negative breast cancer. Aging (Albany NY) 12, 13023-13037.
Datta S, Antonyak MA & Cerione RA (2006) Importance of Ca(2+)-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis. Biochemistry 45, 13163-13174.
Shinde A, Paez JS, Libring S, Hopkins K, Solorio L & Wendt MK (2020) Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche. Oncogenesis 9, 16-28.
Cooper AJ, Sheu KR, Burke JR, Onodera O, Strittmatter WJ, Roses AD & Blass JP (1997) Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc Natl Acad Sci USA 94, 12604-12609.
Iwai K, Shibukawa Y, Yamazaki N & Wada Y (2014) Transglutaminase 2-dependent deamidation of glyceraldehyde-3-phosphate dehydrogenase promotes trophoblastic cell fusion. J Biol Chem 289, 4989-4999.
Esposito C & Caputo I (2005) Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. FEBS J 272, 615-631.
Cordella-Miele E, Miele L, Beninati S & Mukherjee AB (1993) Transglutaminase-catalyzed incorporation of polyamines into phospholipase A2. J Biochem 113, 164-173.
Currò M, Ferlazzo N, Risitano R, Condello S, Vecchio M, Caccamo D & Ientile R (2014) Transglutaminase 2 and phospholipase a₂ interactions in the inflammatory response in human Thp-1 monocytes. Amino Acids 46, 759-766.
Feng JF, Rhee SG & Im MJ (1996) Evidence that phospholipase delta1 is the effector in the Gh (transglutaminase II)-mediated signaling. J Biol Chem 271, 16451-16454.
Kim DS, Park KS & Kim SY (2009) Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors. Front Biosci (Landmark Ed) 14, 2514-2521.
He W, Sun Z & Liu Z (2015) Silencing of TGM2 reverses epithelial to mesenchymal transition and modulates the chemosensitivity of breast cancer to docetaxel. Exp Ther Med 10, 1413-1418.
Budillon A, Carbone C & Di Gennaro E (2013) Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids 44, 63-72.
Eckert RL (2019) Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target. Mol Carcinog 58, 837-853.
Aguiari G, Crudele F, Taccioli C, Minotti L, Corrà F, Keillor JW, Grassilli S, Cervellati C, Volinia S, Bergamini CM et al. (2022) Dysregulation of transglutaminase type 2 through GATA3 defines aggressiveness and doxorubicin sensitivity in breast cancer. Int J Biol Sci 18, 1-14.
Kerr C, Szmacinski H, Fisher ML, Nance B, Lakowicz JR, Akbar A, Keillor JW, Lok Wong T, Godoy-Ruiz R, Toth EA et al. (2017) Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival. Oncogene 36, 2981-2990.
Jambrovics K, Uray IP, Keresztessy Z, Keillor JW, Fésüs L & Balajthy Z (2019) Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation. Haematologica 104, 505-515.
Jambrovics K, Uray IP, Keillor JW, Fésüs L & Balajthy Z (2020) Benefits of combined all-trans retinoic acid and arsenic trioxide treatment of acute promyelocytic leukemia cells and further enhancement by inhibition of atypically expressed transglutaminase 2. Cancers (Basel) 12, 648-662.
Baillie TA (2016) Targeted covalent inhibitors for drug design. Angew Chem Int Ed Engl 55, 13408-13421.
Mader L, Watt SKI, Iyer HR, Nguyen L, Kaur H & Keillor JW (2022) The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors. RSC Med Chem 14, 277-298.
Akbar A, McNeil NMR, Albert MR, Ta V, Adhikary G, Bourgeois K, Eckert RL & Keillor JW (2017) Structure-activity relationships of potent; targeted covalent inhibitors that abolish both the transamidation and GTP binding activities of human tissue transglutaminase. J Med Chem 60, 7910-7927.
Bergamini CM, Dondi A, Lanzara V, Squerzanti M, Cervellati C, Montin K, Mischiati C, Tasco G, Collighan R, Griffin M et al. (2010) Thermodynamics of binding of regulatory ligands to tissue transglutaminase. Amino Acids 39, 297-304.
Rangaswamy AMM, Navals P, Gates EWJ, Shad S, Watt SKI & Keillor JW (2022) Structure-activity relationships of hydrophobic alkyl acrylamides as tissue transglutaminase inhibitors. RSC Med Chem 13, 413-428.
Li C, Li X, Li G, Sun L, Zhang W, Jiang J & Ge Q (2020) Identification of a prognosis-associated signature associated with energy metabolism in triple-negative breast cancer. Oncol Rep 44, 819-837.
Fujita M, Imadome K, Somasundaram V, Kawanishi M, Karasawa K & Wink DA (2020) Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness. BMC Cancer 20, 929-942.
Schmidt JC, Dougherty BV, Beger RD, Jones DP, Schmidt MA & Mattes WB (2021) Metabolomics as a truly translational tool for precision medicine. Int J Toxicol 40, 413-426.
Pavlova NN & Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23, 27-47.
DeBerardinis RJ & Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2, e1600200.
Draguet A, Tagliatti V & Colet JM (2021) Targeting metabolic reprogramming to improve breast cancer treatment: an in vitro evaluation of selected metabolic inhibitors using a metabolomic approach. Metabolites 11, 556-575.
Uifălean A, Schneider S, Gierok P, Ionescu C, Iuga CA & Lalk M (2016) The impact of soy isoflavones on MCF-7 and MDA-MB-231 breast cancer cells using a global metabolomic approach. Int J Mol Sci 17, 1443-1460.
Costantini S, Guerriero E, Teta R, Capone F, Caso A, Sorice A, Romano G, Ianora A, Ruocco N, Budillon A et al. (2017) Evaluating the effects of an organic extract from the mediterranean sponge geodia cydonium on human breast cancer cell lines. Int J Mol Sci 18, 2112-2124.
Maria RM, Altei WF, Selistre-de-Araujo HS & Colnago LA (2017) Effects of doxorubicin; cisplatin; and tamoxifen on the metabolic profile of human breast cancer MCF-7 cells as determined by 1H high-resolution magic angle spinning nuclear magnetic resonance. Biochemistry 56, 2219-2224.
Maria RM, Altei WF, Selistre-de-Arauj HS & Colnago LA (2017) Impact of chemotherapy on metabolic reprogramming: characterization of the metabolic profile of breast cancer MDA-MB-231 cells using 1H HR-MAS NMR spectroscopy. J Pharm Biomed Anal 146, 324-328.
Zhou X, Li Z, Wang X, Jiang G, Shan C & Liu S (2020) Metabolomics reveals the effect of valproic acid on MCF-7 and MDA-MB-231 cells. Xenobiotica 50, 252-260.
Del Coco L, Majellaro M, Boccarelli A, Cellamare S, Altomare CD & Fanizzi FP (2020) Novel antiproliferative biphenyl nicotinamide: NMR metabolomic study of its effect on the MCF-7 cell in comparison with cisplatin and vinblastine. Molecules 25, 3502-3516.
Zhang B, Fu R, Duan Z, Shen S, Zhu C & Fan D (2022) Ginsenoside CK induces apoptosis in triple-negative breast cancer cells by targeting glutamine metabolism. Biochem Pharmacol 202, 115101-115120.
Bhute VJ, Ma Y, Bao X & Palecek SP (2016) The poly (ADP-ribose) polymerase inhibitor veliparib and radiation cause significant cell line dependent metabolic changes in breast cancer cells. Sci Rep 6, 36061-36073.
Lemma S, Di Pompo G, Porporato PE, Sboarina M, Russell S, Gillies RJ, Baldini N, Sonveaux P & Avnet S (2017) MDA-MB-231 breast cancer cells fuel osteoclast metabolism and activity: a new rationale for the pathogenesis of osteolytic bone metastases. Biochim Biophys Acta Mol Basis Dis 1863, 3254-3264.
Lanning NJ, Castle JP, Singh SJ, Leon AN, Tovar EA, Sanghera A, MacKeigan JP, Filipp FV & Graveel CR (2017) Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities. Cancer Metab 5, 6-20.
Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC et al. (2021) Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab 33, 51-64.
Bao L, Hazari S, Mehra S, Kaushal D, Moroz K & Dash S (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180, 2490-2503.
Abu Ajaj K, Graeser R & Kratz F (2012) Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin. Breast Cancer Res Treat 134, 117-129.
Verhaar R, Jongenelen CA, Gerard M, Baekelandt V, Van Dam AM, Wilhelmus MM & Drukarch B (2011) Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of α-synuclein in a cellular model of Parkinson's disease. Neurochem Int 58, 785-793.
Yamaguchi H & Wang HG (2006) Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol 26, 569-579.
Malkomes P, Lunger I, Oppermann E, Abou-El-Ardat K, Oellerich T, Günther S, Canbulat C, Bothur S, Schnütgen F, Yu W et al. (2021) Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53. Oncogene 40, 4352-4367.
McNeil NMR, Gates EWJ, Firoozi N, Cundy NJ, Leccese J, Eisinga S, Tyndall JDA, Adhikary G, Eckert RL & Keillor JW (2022) Structure-activity relationships of N-terminal variants of peptidomimetic tissue transglutaminase inhibitors. Eur J Med Chem 232, 114172-114196.
Sonkar K, Ayyappan V, Tressler CM, Adelaja O, Cai R, Cheng M & Glunde K (2016) Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed 32, e4112-e4174.
Mattaini KR, Sullivan MR & Vander Heiden MG (2016) The importance of serine metabolism in cancer. J Cell Biol 214, 249-257.
Arike L, Hansson GC & Recktenwald CV (2020) Identifying transglutaminase reaction products via mass spectrometry as exemplified by the MUC2 mucin - pitfalls and traps. Anal Biochem 597, 113668-113673.
Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA & Brown KD (2008) The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 29, 510-518.
Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M & Budillon A (2017) Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. Amino Acids 49, 517-528.
Hlaváč V, Václavíková R, Brynychová V, Koževnikovová R, Kopečková K, Vrána D, Gatěk J & Souček P (2020) Role of genetic variation in ABC transporters in breast cancer prognosis and therapy response. Int J Mol Sci 21, 9556-9573.
Cundy NJ, Arciszewski J, Gates EWJ, Acton SL, Passley KD, Awoonor-Williams E, Boyd EK, Xu N, Pierson E, Fernandez-Ansieta C et al. (2022) Novel irreversible peptidic inhibitors of transglutaminase 2. Rsc Med Chem 14, 378-385.
Podo F, Paris L, Cecchetti S, Spadaro F, Abalsamo L, Ramoni C, Ricci A, Pisanu ME, Sardanelli F, Canese R et al. (2016) Activation of phosphatidylcholine-specific phospholipase C in breast and ovarian cancer: impact on MRS-detected choline metabolic profile and perspectives for targeted therapy. Front Oncol 6, 171-179.
Muthusamy T, Cordes T, Handzlik MK, You L, Lim EW, Gengatharan J, Pinto AFM, Badur MG, Kolar MJ, Wallace M et al. (2020) Serine restriction alters sphingolipid diversity to constrain tumour growth. Nature 586, 790-795.
Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Maelandsmo GM et al. (2014) Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Res 16, R5-R21.
Kang SK, Yi KS, Kwon NS, Park KH, Kim UH, Baek KJ & Im MJ (2004) Alpha1B-adrenoceptor signaling and cell motility: GTPase function of Gh/transglutaminase 2 inhibits cell migration through interaction with cytoplasmic tail of integrin alpha subunits. J Biol Chem 279, 36593-36600.
Iismaa SE, Begg GE & Graham RM (2006) Cross-linking transglutaminases with G protein-coupled receptor signaling. Sci STKE 353, pe34.
Huang SP, Liu PY, Kuo CJ, Chen CL, Lee WJ, Tsai YH & Lin YF (2017) The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer. J Hematol Oncol 10, 114-127.
D'Eletto M, Rossin F, Occhigrossi L, Farrace MG, Faccenda D, Desai R, Marchi S, Refolo G, Falasca L, Antonioli M et al. (2018) Transglutaminase type 2 regulates ER-mitochondria contact sites by interacting with GRP75. Cell Rep 25, 3573-3581.e4.
Malorni W, Farrace MG, Matarrese P, Tinari A, Ciarlo L, Mousavi-Shafaei P, D'Eletto M, Di Giacomo G, Melino G, Palmieri L et al. (2009) The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrial-dependent apoptosis. Cell Death Differ 16, 1480-1492.
Sedano MJ, Ramos EI, Choudhari R, Harrison AL, Subramani R, Lakshmanaswamy R, Zilaie M & Gadad SS (2020) Hypoxanthine phosphoribosyl transferase 1 is upregulated; predicts clinical outcome and controls gene expression in breast cancer. Cancers (Basel) 12, 1522-1535.
Chhetri DR (2019) Myo-inositol and its derivatives: their emerging role in the treatment of human diseases. Front Pharmacol 10, 1172-1180.
Deng F, Zheng X, Sharma I, Dai Y, Wang Y & Kanwar YS (2021) Regulated cell death in cisplatin-induced AKI: relevance of myo-inositol metabolism. Am J Physiol Renal Physiol 320, F578-F595.
Amabile MI, De Luca A, Tripodi D, D'Alberti E, Melcarne R, Imbimbo G, Picconi O, D'Andrea V, Vergine M, Sorrenti S et al. (2021) Effects of inositol hexaphosphate and myo-inositol administration in breast cancer patients during adjuvant chemotherapy. J Pers Med 11, 756-771.
Comşa Ş, Cîmpean AM & Raica M (2015) The story of MCF-7 breast cancer cell line: 40 years of experience in research. Anticancer Res 35, 3147-3154.
Huang Z, Yu P & Tang J (2020) Characterization of triple-negative breast cancer MDA-MB-231 cell spheroid model. Onco Targets Ther 13, 5395-5405.
Franzese O, Minotti L, Aguiari G, Corrà F, Cervellati C, Ferrari C, Volinia S, Bergamini CM & Bianchi N (2019) Involvement of non-coding RNAs and transcription factors in the induction of transglutaminase isoforms by ATRA. Amino Acids 51, 1273-1288.
Gallo M, Giovati L, Magliani W, Pertinhez TA, Conti S, Ferrari E, Spisni A & Ciociola T (2022) Metabolic plasticity of candida albicans in response to different environmental conditions. J Fungi (Basel) 8, 723-738.
Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, Gauthier C, Jacques PÉ, Li S & Xia J (2021) MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res 49, W388-W396.
Worley B & Powers R (2013) Multivariate analysis in metabolomics. Curr Metabolomics 1, 92-107.